| Autor: |
Lozinski A; Department of Dermatology, Sheba Medical Center, Tel Hashomer, Ramat Gan. alinalozin@gmail.com, Baum S, Sagi L, Volkov A, Trau H, Barzilai A |
| Jazyk: |
hebrejština |
| Zdroj: |
Harefuah [Harefuah] 2012 Oct; Vol. 151 (10), pp. 562-5, 606. |
| Abstrakt: |
Autoimmune bullous skin disorders are characterized by a severe and potentially lethal course and may require aggressive long-term treatment with systemic corticosteroids and other immunosuppressive drugs, which can lead to serious adverse events. Recently, anti-CD20 antibody, Rituximab, was reported to be beneficial as an adjuvant therapy in these diseases. Herein, we present 2 case reports of patients suffering from resistant rare diseases from the aforementioned spectrum: linear IgA dermatosis and Pemphigoid gestationis. The patients were successfully treated with Rituximab (Mabthera). This is one of the first reports of this kind of treatment for these rare life-threatening diseases. These case reports emphasize the role of Rituximab as a crisis therapy in autoimmune blistering diseases. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
